Galderma launched “We Are All Sculptra”, showcasing Sculptra’s regenerative versatility across diverse patient demographics. The programme tracks nine treatment-naïve participants over two years. It delivers longitudinal insights into tailoring regenerative biostimulation across ages, skin types, ethnicities, and aesthetic goals. Through structured clinical documentation, standardised imaging, and patient-reported video diaries, the initiative provides real-world evidence of outcomes in routine practice settings. ...
Menopause causes profound biological changes that directly affect the skin. Yet, these changes remain under-recognised in dermatology and aesthetic practice. At IMCAS 2026 in Paris, Galderma addressed this gap with new global survey data on clinical trial inclusivity. Global survey reveals common skin concerns Galderma presented findings from a global survey involving more than 4,300 peri- and post-menopausal women. The ...
The medical aesthetics market in Asia Pacific is experiencing rapid growth. It is expected to rise from US$ 4.8 billion in 2024 to US$ 17.9 billion by 2034. This growth reflects a compound annual growth rate (CAGR) of 14.1 per cent. It highlights a significant expansion in the demand for non-surgical aesthetic treatments. Key market drivers More people are becoming ...
The world of aesthetic medicine is a fascinating one, constantly evolving to meet the changing preferences of patients and advancements in technology. And this year is no exception! The latest aesthetic trends are all about subtle enhancements that prioritize safety and efficacy, individuality, and overall well-being. From prejuvenation to weight-loss shots and medications, exosome therapy to natural-looking enhancements, injectable treatments ...